The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Fibroblast Growth Factor 23 and Mortality among Patients Undergoing Hemodialysis
Open accessAbstract
BACKGROUND: Fibroblast growth factor 23 (FGF-23) is a hormone that increases the rate of urinary excretion of phosphate and inhibits renal production of 1,25-dihydroxyvitamin D, thus helping to mitigate hyperphosphatemia in patients with kidney disease. Hyperphosphatemia and low 1,25-dihydroxyvitamin D levels are associated with mortality among patients with chronic kidney disease, but the effect of the level of FGF-23 on mortality is unknown. METHODS: We examined mortality according to serum phosphate levels in a prospective cohort of 10,044 patients who were beginning hemodialysis treatment and then analyzed FGF-23 levels and mortality in a nested case-control sample of 200 subjects who died and 200 who survived during the first year of hemodialysis treatment. We hypothesized that increased FGF-23 levels at the initiation of hemodialysis would be associated with increased mortality. RESULTS: Serum phosphate levels in the highest quartile (>5.5 mg per deciliter [1.8 mmol per liter]) were associated with a 20% increase in the multivariable adjusted risk of death, as compared with normal levels (3.5 to 4.5 mg per deciliter [1.1 to 1.4 mmol per liter]) (hazard ratio, 1.2; 95% confidence interval [CI], 1.1 to 1.4). Median C-terminal FGF-23 (cFGF-23) levels were significantly higher in case subjects than in controls (2260 vs. 1406 reference units per milliliter, P<0.001). Multivariable adjusted analyses showed that increasing FGF-23 levels were associated with a monotonically increasing risk of death when examined either on a continuous scale (odds ratio per unit increase in log-transformed cFGF-23 values, 1.8; 95% CI, 1.4 to 2.4) or in quartiles, with quartile 1 as the reference category (odds ratio for quartile 2, 1.6 [95% CI, 0.8 to 3.3]; for quartile 3, 4.5 [95% CI, 2.2 to 9.4]; and for quartile 4, 5.7 [95% CI, 2.6 to 12.6]). CONCLUSIONS: Increased FGF-23 levels appear to be independently associated with mortality among patients who are beginning hemodialysis treatment. Future studies might investigate whether FGF-23 is a potential biomarker that can be used to guide strategies for the management of phosphorus balance in patients with chronic kidney disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E., & Hsu, C.-Y. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041031 · Cited by 11,369
Mineral Metabolism, Mortality, and Morbidity in Maintenance Hemodialysis
Block, G. A., Klassen, P. S., Lazarus, J. M., Ofsthun, N., Lowrie, E. G., & Chertow, G. M. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000133041.27682.a2 · Cited by 2,687
Shimada, T., Kakitani, M., Yamazaki, Y., Hasegawa, H., Takeuchi, Y., Fujita, T., Fukumoto, S., Tomizuka, K., & Yamashita, T. (2004) · Journal of Clinical Investigation · doi:10.1172/jci19081 · Cited by 1,596
Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23
White, K. E., Evans, W. E., O'Riordan, J. L. H., Speer, M. C., Econs, M. J., Lorenz-Depiereux, B., Grabowski, M., Meitinger, T., & Strom, T. M. (2000) · Nature Genetics · doi:10.1038/81664 · Cited by 1,528
Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia
Shimada, T., Mizutani, S., Muto, T., Yoneya, T., Hino, R., Takeda, S., Takeuchi, Y., Fujita, T., Fukumoto, S., & Yamashita, T. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.101545198 · Cited by 1,457
Serum Phosphate Levels and Mortality Risk among People with Chronic Kidney Disease
Kestenbaum, B., Sampson, J. N., Rudser, K. D., Patterson, D. J., Seliger, S. L., Young, B., Sherrard, D. J., & Andress, D. L. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004070602 · Cited by 1,226
The parathyroid is a target organ for FGF23 in rats
Ben-Dov, I. Z., Galitzer, H., Lavi-Moshayoff, V., Goetz, R., Kuro-o, M., Mohammadi, M., Sirkis, R., Naveh-Many, T., & Silver, J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32409 · Cited by 951
Survival of Patients Undergoing Hemodialysis with Paricalcitol or Calcitriol Therapy
Teng, M., Wolf, M., Lowrie, E., Ofsthun, N., Lazarus, J. M., & Thadhani, R. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022536 · Cited by 927
Self-citationGutierrez, O., Isakova, T., Rhee, E., Shah, A., Holmes, J., Collerone, G., Ju[Combining Diaeresis]ppner, H., & Wolf, M. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005010052 · Cited by 921
Self-citationFibroblast Growth Factor 23 in Oncogenic Osteomalacia and X-Linked Hypophosphatemia
Jonsson, K. B., Zahradnik, R., Larsson, T., White, K. E., Sugimoto, T., Imanishi, Y., Yamamoto, T., Hampson, G., Koshiyama, H., Ljunggren, Ö., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020881 · Cited by 914
Self-citationKalantar-Zadeh, K., Kuwae, N., Regidor, D. L., Kovesdy, C. P., Kilpatrick, R. D., Shinaberger, C. S., McAllister, C. J., Budoff, M. J., Salusky, I. B., & Kopple, J. D. (2006) · Kidney International · doi:10.1038/sj.ki.5001514 · Cited by 905
Relation Between Serum Phosphate Level and Cardiovascular Event Rate in People With Coronary Disease
Tonelli, M., Sacks, F., Pfeffer, M., Gao, Z., & Curhan, G. (2005) · Circulation · doi:10.1161/circulationaha.105.553198 · Cited by 885
Vitamin D levels and early mortality among incident hemodialysis patients
Wolf, M., Shah, A., Gutierrez, O., Ankers, E., Monroy, M., Tamez, H., Steele, D., Chang, Y., Camargo, C. A., Tonelli, M., et al. (2007) · Kidney International · doi:10.1038/sj.ki.5002451 · Cited by 789
Self-citationActivated Injectable Vitamin D and Hemodialysis Survival: A Historical Cohort Study
Teng, M., Wolf, M., Ofsthun, M. N., Lazarus, J. M., Hernán, M. A., Camargo, C. A., & Thadhani, R. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004070573 · Cited by 782
Self-citationLarsson, T., Nisbeth, U. L. F., Ljunggren, Ö., Jüppner, H., & Jonsson, K. B. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00328.x · Cited by 689
Self-citationDisparities in Incidence of Diabetic End-Stage Renal Disease According to Race and Type of Diabetes
Cowie, C. C., Port, F. K., Wolfe, R. A., Savage, P. J., Moll, P. P., & Hawthorne, V. M. (1989) · New England Journal of Medicine · doi:10.1056/nejm198910193211603 · Cited by 508
An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia
Benet-Pagès, A., Orlik, P., Strom, T. M., & Lorenz-Depiereux, B. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi034 · Cited by 507
Circulating FGF-23 Is Regulated by 1α,25-Dihydroxyvitamin D3 and Phosphorus in Vivo
Saito, H., Maeda, A., Ohtomo, S.-I., Hirata, M., Kusano, K., Kato, S., Ogata, E., Segawa, H., Miyamoto, K.-I., & Fukushima, N. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m408903200 · Cited by 471
Regulation of C-Terminal and Intact FGF-23 by Dietary Phosphate in Men and Women
Burnett, S.-A. M., Gunawardene, S. C., Bringhurst, F. R., Jüppner, H., Lee, H., & Finkelstein, J. S. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.060507 · Cited by 455
Self-citationEvidence for alteration of the vitamin D-endocrine system in blacks.
Bell, N. H., Greene, A., Epstein, S., Oexmann, M. J., Shaw, S., & Shary, J. (1985) · Journal of Clinical Investigation · doi:10.1172/jci111995 · Cited by 454
Dietary Phosphorus Regulates Serum Fibroblast Growth Factor-23 Concentrations in Healthy Men
Antoniucci, D. M., Yamashita, T., & Portale, A. A. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0021 · Cited by 421
Melamed, M. L., Eustace, J. A., Plantinga, L., Jaar, B. G., Fink, N. E., Coresh, J., Klag, M. J., & Powe, N. R. (2006) · Kidney International · doi:10.1038/sj.ki.5001542 · Cited by 354
White, K. E. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.2.497 · Cited by 329
Shigematsu, T., Kazama, J. J., Yamashita, T., Fukumoto, S., Hosoya, T., Gejyo, F., & Fukagawa, M. (2004) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2004.04.029 · Cited by 326
Stubbs, J. R., Liu, S., Tang, W., Zhou, J., Wang, Y., Yao, X., & Quarles, L. D. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006121385 · Cited by 276
Pathogenesis of vascular calcification in chronic kidney disease
Cozzolino, M., Brancaccio, D., Gallieni, M., & Slatopolsky, E. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00421.x · Cited by 240
Analysis of the Biochemical Mechanisms for the Endocrine Actions of Fibroblast Growth Factor-23
Yu, X., Ibrahimi, O. A., Goetz, R., Zhang, F., Davis, S. I., Garringer, H. J., Linhardt, R. J., Ornitz, D. M., Mohammadi, M., & White, K. E. (2005) · Endocrinology · doi:10.1210/en.2005-0670 · Cited by 213
Tumors Associated With Oncogenic Osteomalacia Express Genes Important in Bone and Mineral Metabolism
De Beur, S. M. J., Finnegan, R. B., Vassiliadis, J., Cook, B., Barberio, D., Estes, S., Manavalan, P., Petroziello, J., Madden, S. L., Cho, J. Y., et al. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.6.1102 · Cited by 212
Impact of Activated Vitamin D and Race on Survival among Hemodialysis Patients
Wolf, M., Betancourt, J., Chang, Y., Shah, A., Teng, M., Tamez, H., Gutierrez, O., Camargo, C. A., Melamed, M., Norris, K., et al. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007091002 · Cited by 161
Self-citationSitara, D., Razzaque, M. S., St‐Arnaud, R., Huang, W. Y., Taguchi, T., Erben, R. G., & Lanske, B. (2006) · American Journal Of Pathology · doi:10.2353/ajpath.2006.060329 · Cited by 153
Koiwa, F., Kazama, J. J., Tokumoto, A., Onoda, N., Kato, H., Okada, T., Nii‐Kono, T., Fukagawa, M., & Shigematsu, T. (2005) · Therapeutic Apheresis and Dialysis · doi:10.1111/j.1744-9987.2005.00293.x · Cited by 138
Nagano, N., Miyata, S., Abe, M., Kobayashi, N., Wakita, S., Yamashita, T., & Wada, M. (2006) · Kidney International · doi:10.1038/sj.ki.5000020 · Cited by 138
Skeletal abnormalities in chronic renal insufficiency before and during maintenance hemodialysis
Ritz, E., Krempien, B., Mehls, O., & Malluche, H. H. (1973) · Kidney International · doi:10.1038/ki.1973.90 · Cited by 102
Robinson, B. M., Joffe, M. M., Pisoni, R. L., Port, F. K., & Feldman, H. I. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005101078 · Cited by 92
Prevalence and severity of disordered mineral metabolism in Blacks with chronic kidney disease
Gutiérrez, O. M., Isakova, T., Andress, D. L., Levin, A., & Wolf, M. S. (2008) · Kidney International · doi:10.1038/ki.2008.4 · Cited by 79
Self-citationFrankenfield, D. L., Rocco, M. V., Roman, S. H., & McClellan, W. M. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000037400.83593.e6 · Cited by 61
Foley, R. N., Wang, C., Ishani, A., & Collins, A. J. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006121411 · Cited by 49
Cited by
FGF23 induces left ventricular hypertrophy
Faul, C., Amaral, A. P., Oskouei, B., Hu, M.-C., Sloan, A., Isakova, T., Gutiérrez, O. M., Aguillon-Prada, R., Lincoln, J., Hare, J. M., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46122 · Cited by 2,027
Self-citationThe FGF family: biology, pathophysiology and therapy
Beenken, A., & Mohammadi, M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2792 · Cited by 1,945
Isakova, T., on behalf of the Chronic Renal Insufficiency Cohort (CRIC) Study Group, Wahl, P., Vargas, G. S., Gutiérrez, O. M., Scialla, J., Xie, H., Appleby, D., Nessel, L., Bellovich, K., et al. (2011) · Kidney International · doi:10.1038/ki.2011.47 · Cited by 1,266
Self-citationIsakova, T. (2011) · JAMA · doi:10.1001/jama.2011.826 · Cited by 1,020
Self-citationEffect of Cinacalcet on Cardiovascular Disease in Patients Undergoing Dialysis
The EVOLVE Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1205624 · Cited by 971
Metadata
- Authors
- Gutiérrez, O. M., Mannstadt, M., Isakova, T., Rauh-Hain, J. A., Tamez, H., Shah, A., Smith, K., Lee, H., Thadhani, R., Jüppner, H., & Wolf, M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-08-07
- Volume
- 359
- Issue
- 6
- Pages
- 584-592
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1977645780
- Cited by
- 1,727
- References
- 37
- FWCI
- 75.83
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.